R.T. Hughes

Radiation-Induced Bone Toxicity

Purpose of ReviewNormal bone is commonly irradiated during radiation therapy (RT). The true impact of focal radiation on bone tissue remains unclear. The goal of this paper is to present the current understanding of radiation effects on the bone as it pertains to clinically observed radiation side effects.Recent FindingsAn increased risk of local fracture has been associated with RT-induced bone loss in the pelvis, vertebrae, and ribs. This bone loss appears to occur early after and/or during treatment, which suggests that reactive remodeling of the bone via osteoclast activity is a primary contributor to bone loss and fractures.SummarySeveral reports have quantified the structural and histological changes observed after bone irradiation. These include changes in bone density and cortical thickness, as well as alterations in both the number and activity of the cells responsible for bone turnover that arise from hematopoietic and mesenchymal lineages: namely, osteoclasts and osteoblasts. All of these changes likely play an important role in the increased risk of fracture reported with RT. However, more research is needed to fully understand the mechanisms of bone damage and its relationship to modifiable factors such as beam energy, dose, photon or charged particle radiation, linear energy transfer (LET), fractionation, and field size.

Potential Prognostic Markers for Survival and Neurologic Death in Patients with Breast Cancer Brain Metastases who Receive upfront SRS Alone

Purpose/Objectives Stereotactic radiosurgery (SRS) is used as a treatment option for breast cancer brain metastases. It is unclear what factors predict neurologic death for these patients. Materials/Methods A total of 128 patients with breast cancer brain metastases were treated with upfront SRS alone in this study. Survival was estimated using the Kaplan-Meier method. Clinicopathologic factors evaluated included age, ER/PR status, Her2 status, numbers of brain metastases treated, minimum SRS dose, disease-specific GPA, extracranial disease status and systemic disease burden. Results ER or PR positivity was associated with a trend towards decreased neurologic death (subdistribution hazard ratio (sHR) = 0.54, p=0.06). Factors associated with non-neurologic death include extracranial disease status (sHR = 2.02, p=0.02) and dose (sHR = 1.11, p=0.02); Her2-positivity was associated with reduced hazard of non-neurologic death (sHR 0.52, p=0.05). Conclusions ER/PR positivity was associated with a trend towards less neurologic death. HER2 positivity was associated with a trend towards less non-neurologic death.

The number of prior lines of systemic therapy as a prognostic factor for patients with brain metastases treated with stereotactic radiosurgery: Results of a large single institution retrospective analysis

OBJECTIVES It is presently unknown whether patients with brain metastases from heavily pre-treated cancers have a significantly different prognosis than those with less pre-treatment. In this study we sought to identify whether the number of prior lines of systemic therapy are associated with clinical outcomes in patients with brain metastases who received stereotactic radiosurgery (SRS). PATIENTS AND METHODS Between July 2000 and July 2017, 377 patients with brain metastases were treated with upfront SRS. We performed a large, single institution retrospective analysis of these patients. Kaplan Meier analysis was used to estimate survival times. Competing risk analysis was used to estimate times to local failure (LF) and distant brain failure (DBF). Multivariate analysis was performed to estimate the hazard ratios (HRs) for overall survival (OS), neurologic and non-neurologic death for patients with 1, 2 and 3+ lines of prior systemic therapy. RESULTS Of the 1077 patients with brain metastases treated with SRS, 377 received prior systemic therapy with a median of 1 (range: 1-9) lines of prior therapy. Median OS was 8.70 months (95% CI, 7.9-9.5). Median OS for patients with 1 prior line of therapy, 2 prior lines of therapy and 3 or greater lines of therapy were 9.93-, 9.05-, and 6.18-months, respectively (log rank p = .04). Lines of therapy as a continuous variable was not associated with LF or DBF on competing risk analysis. The percentage of patients that died of neurological death was 36%. Greater prior lines of therapy (1 vs. 2 vs. 3 and greater) was associated with a greater likelihood of dying of non-neurologic death (grays p = .01), but was not associated with likelihood of dying of neurologic death (p = .57). CONCLUSION Lines of therapy are associated with OS and non-neurologic death but are not associated with neurologic death, LF or DBF.

Histiocytic Sarcoma Associated with Follicular Lymphoma: Evidence for Dramatic Response with Rituximab and Bendamustine Alone and a Review of the Literature

Histiocytic sarcoma (HS) is a rare aggressive malignancy with a dismal prognosis and no agreed-upon standard treatment. Classically, the diagnosis of HS has been difficult to confirm and has relied on inaccurate, crude techniques. Therapy often involves intensive chemotherapeutic regimens, surgery, and/or radiotherapy, which are poorly tolerated with variable response rates. Patients often die of diffusely metastatic disease. Modern diagnostic techniques are helping to slowly uncover more uniquely customized therapeutic approaches in this enigmatic disease. We present a review of the current literature regarding HS diagnosis, treatment, and outcomes. Additionally, we describe the first reported case of HS transdifferentiated from follicular lymphoma that had a dramatic and durable response to rituximab/bendamustine alone as initial treatment. Unlike traditional chemotherapy regimens, this treatment was well tolerated and had a good toxicity profile. The combination of rituximab and bendamustine warrants further investigation in the treatment of HS, especially those originating from prior follicular lymphoma. Modern immunohistochemical and molecular profiling techniques are beginning to reveal heterogeneity among HS tumors and potentially therapeutic targets.